VTYX (Ventyx Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

VTYX (Ventyx Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

VTYXVentyx Biosciences, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$107M

EPS (TTM)-$1.50

Free Cash Flow (TTM)-$88M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$39M
Q1 23	$0	$0	-$43M
Q2 23	$0	$0	-$57M
Q3 23	$0	$0	-$58M
Q4 23	$0	$0	-$50M
Q1 24	$0	-$408K	-$42M
Q2 24	$0	-$316K	-$36M
Q3 24	$0	$0	-$39M
Q4 24	$0	$0	-$32M
Q1 25	$0	$0	-$30M
Q2 25	$0	$0	-$29M
Q3 25	$0	$0	-$25M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$47M	-$47M
Q1 23	-$31M	-$31M
Q2 23	-$49M	-$49M
Q3 23	-$35M	-$35M
Q4 23	-$52M	-$52M
Q1 24	-$48M	-$48M
Q2 24	-$25M	-$25M
Q3 24	-$35M	-$35M
Q4 24	-$23M	-$23M
Q1 25	-$26M	-$26M
Q2 25	-$21M	-$21M
Q3 25	-$18M	-$18M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$112K
Q1 23	$60K
Q2 23	$195K
Q3 23	$48K
Q4 23	$211K
Q1 24	$175K
Q2 24	$60K
Q3 24	$0
Q4 24	$6K
Q1 25	$16K
Q2 25	$42K
Q3 25	$50K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+116.4%
Q1 23	—	+87.1%
Q2 23	—	+180.2%
Q3 23	—	+84.4%
Q4 23	—	+30.5%
Q1 24	—	-1.8%
Q2 24	—	-37.5%
Q3 24	—	-33.5%
Q4 24	—	-35.6%
Q1 25	—	-27.9%
Q2 25	—	-17.9%
Q3 25	—	-35.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$5M	—
Q1 23	$7M	—
Q2 23	$8M	—
Q3 23	$8M	—
Q4 23	$6M	—
Q1 24	$7M	—
Q2 24	$6M	—
Q3 24	$5M	—
Q4 24	$5M	—
Q1 25	$5M	—
Q2 25	$5M	—
Q3 25	$5M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 22	$30M	$8M
Q1 23	$35M	$7M
Q2 23	$49M	$9M
Q3 23	$50M	$8M
Q4 23	$42M	$8M
Q1 24	$34M	$8M
Q2 24	$28M	$8M
Q3 24	$31M	$8M
Q4 24	$25M	$8M
Q1 25	$23M	$7M
Q2 25	$22M	$7M
Q3 25	$18M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$65M	$253M	$318M
Q1 23	$64M	$313M	$377M
Q2 23	$52M	$281M	$332M
Q3 23	$57M	$244M	$301M
Q4 23	$52M	$201M	$252M
Q1 24	$142M	$161M	$303M
Q2 24	$41M	$199M	$239M
Q3 24	$62M	$213M	$275M
Q4 24	$27M	$190M	$217M
Q1 25	$28M	$201M	$229M
Q2 25	$32M	$177M	$209M
Q3 25	$32M	$161M	$193M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	57M	+9.8%
Q1 23	58M	+1.6%
Q2 23	59M	+1.6%
Q3 23	59M	+0.6%
Q4 23	59M	+0.3%
Q1 24	62M	+4.7%
Q2 24	71M	+14.1%
Q3 24	71M	+0.2%
Q4 24	71M	+0.2%
Q1 25	71M	+0.5%
Q2 25	71M	+0.1%
Q3 25	71M	+0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	27
FY 22	$0	58
FY 23	$0	79
FY 24	$0	79